OncoMatch/Clinical Trials/NCT02131753
Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Is NCT02131753 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Cladribine s.c. for hairy cell leukemia.
Treatment: Cladribine s.c. — The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment. They have to be untreated so far or may be pretreated with alpha-interferon.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hairy Cell Leukemia
Performance status
WHO 0–2
Prior therapy
Cannot have received: purine analogues
Pretreatment with purine analogues or other chemotherapeutics
Cannot have received: cytostatic chemotherapy
No previous cytostatic treatment
Cannot have received: other chemotherapeutics
Pretreatment with purine analogues or other chemotherapeutics
Lab requirements
Kidney function
creatinin > 2 mg/dl or creatinine clearance < 50 ml/min
Liver function
bilirubin > 2 mg/dl, alkaline phosphatase, glutamate-oxalacetate transaminase and glutamate-pyruvate transaminase > 2 x upper limit of normal
Cardiac function
severe dysfunction of the heart (NYHA III or IV)
Severe dysfunction of the heart (NYHA III or IV), the lung (WHO-Grade III or IV), the liver, except due to lymphoma (bilirubin > 2 mg/dl, alkaline phosphatase, glutamate-oxalacetate transaminase and glutamate-pyruvate transaminase > 2 x upper limit of normal), the kidneys (creatinin > 2 mg/dl or creatinine clearance < 50 ml/min)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify